• 1
    Reavill C, Stolerman IP. Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br J Pharmacol 1990;99:273278.
  • 2
    Corrigall WA, Coen KM. Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology 1991;104:171176.
  • 3
    Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology 1997;130:2840.
  • 4
    Laviolette SR, Van Der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol Psychiatry 2003;8:5059.
  • 5
    Clarke PBS, Fu DS, Jakubovic A, Fibiger HC. Evidence that Mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988;246:701708.
  • 6
    Louis M, Clarke PB. Effect of ventral tegmental 6-hydroxydopamine lesions on the locomotor stimulant action of nicotine in rats. Neuropharmacology 1998;37:15031513.
  • 7
    Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001;70:439446.
  • 8
    Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988;85:52745278.
  • 9
    Schilström B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: Putative role of α7 nicotinic receptors in the ventral tegmental area. Neuroscience 1998;85:10051009.
  • 10
    Imperato A, Mulas A, Di Chiara G. Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986;132:337338.
  • 11
    Marshall DL, Redfern PH, Wonnacott S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: Comparison of naive and chronic nicotine-treated rats. J Neurochem 1997;68:15111519.
  • 12
    Di Matteo V, Pierucci M, Esposito E. Selective stimulation of serotonin2c receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration. J Neurochem 2004;89:418429.
  • 13
    Clarke PBS, Hommer DW, Pert A, Skirboll LR. Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol 1985;85:827835.
  • 14
    Calabresi P, Lacey MG, North RA. Nicotinic excitation of rat ventral tegmental neurones in vitro studied by intracellular recording. Br J Pharmacol 1989;98:135140.
  • 15
    Sorenson EM, Shiroyama T, Kitai ST. Postsynaptic nicotinic receptors on dopaminergic neurons in the substantia nigra pars compacta of the rat. Neuroscience 1998;87:659673.
  • 16
    Schilström B, Rawal N, Mameli-Engvall M, Nomikos GG, Svensson TH. Dual effects of nicotine on dopamine neurons mediated by different receptor subtypes. Int J Neuropsychopharmacol 2003;6:111.
  • 17
    Schilström B, Mameli-Engvall M, Rawal N, Grillner P, Jardemark K, Svensson TH. Nitric oxide is involved in nicotine-induced burst firing of rat ventral tegmental area dopamine neurons. Neuroscience 2004;125:957964.
  • 18
    Pierucci M, Di Matteo V, Esposito E. Stimulation of serotonin2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration. J Pharmacol Exp Ther 2004;309:109118.
  • 19
    Mifsud J-C, Hernandez L, Hoebel BG. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res 1989;478:365367.
  • 20
    Ferrari R, Le Nove're N, Picciotto MR, Changeux JP, Zoli M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 2002;15:18101818.
  • 21
    Di Matteo V, Pierucci M, Benigno A, Crescimanno G, Esposito E, Di Giovanni G. Involvement of nitric oxide in 6-OHDA-induced neurodegeneration: A neurochemical study. Ann N Y Acad Sci 2009;1155,309315.
  • 22
    Di Matteo V, Pierucci M, Benigno A, Orbán G, Crescimanno G, Esposito E, Di Giovanni G. Electrophysiological and neurochemical characterization of 7-Nitroindazole and molsidomine acute and subchronic administration effects in the dopaminergic nigrostriatal system in rats. J Neural Transm Suppl 2009;73,173182.
  • 23
    McLeod TM, López-Figueroa AL, López-Figueroa MO. Nitric oxide, stress, and depression. Psychopharmacol Bull 2001;35:2441.
  • 24
    Yao JK, Leonard S, Reddy RD. Increased nitric oxide radicals in post-mortem brain from patients with schizophrenia. Schizophr Bull 2004;30:923934.
  • 25
    Tayfun Uzbay I, Oglesby MW. Nitric oxide and substance dependence. Neurosci Biobehav Rev 2001;25:4352.
  • 26
    West AR, Galloway MP, Grace AA. Regulation of striatal dopamine neurotransmission by nitric oxide: Effector pathways and signalling mechanisms. Synapse 2002;44:227245.
  • 27
    Vleeming W, Rambali B, Opperhuizen A. The role of nitric oxide in cigarette smoking and nicotine addiction. Nicotine Tob Res 2002;4:341348.
  • 28
    Di Giovanni G, Shi WX. Effects of scopolamine on dopamine neurons in the substantia nigra: Role of the pedunculopontine tegmental nucleus. Synapse 2009;63:673680.
  • 29
    Paxinos G, Watson C. The Rat brain in stereotaxic coordinates. New York : Academic Press, 1986.
  • 30
    Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: Burst firing. J Neurosci 1984;4:28772890.
  • 31
    West AR, Grace AA. Striatal nitric oxide signalling regulates the neuronal activity of midbrain dopamine neurons in vivo. J Neurophysiol 2000;83:17961808.
  • 32
    Cox BA, Johnson SW. Nitric oxide facilitates N-methyl-D-aspartate-induced burst firing in dopamine neurons from rat midbrain slices. Neurosci Lett 1998;255:131134.
  • 33
    Nowak P, Brus R, Oświecimska J, Sokoła A, Kostrzewa RM. 7-Nitroindazole enhances amphetamine-evoked dopamine release in rat striatum. An in vivo microdialysis and voltammetric study. J Physiol Pharmacol 2002;53:251263.
  • 34
    Campos F, Alfonso M, Vidal L, Faro LR, Durán R. Mediation of glutamatergic receptors and nitric oxide on striatal dopamine release evoked by anatoxin-a. An in vivo microdialysis study. Eur J Pharmacol 2006;548:9098.
  • 35
    Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383394.
  • 36
    Meyer RC, Spangler EL, Patel N, London ED, Ingram DK. Impaired learning in rats in a 14-unit T-maze by 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, is attenuated by the nitric oxide donor, molsidomine. Eur J Pharmacol 1998;341:1722.
  • 37
    Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N Jr. The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol 1997;10:364368.
  • 38
    Boireau A, Dubedat P, Bordier F, Imperato A, Moussaoui S. The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation. Neuropharmacology 2000;39:10161020.
  • 39
    Thomas B, Saravanan KS, Mohanakumar KP. In vitro and in vivo evidences that antioxidant action contributes to the neuroprotective effects of the neuronal nitric oxide synthase and monoamine oxidase-B inhibitor, 7-nitroindazole. Neurochem Int 2008;52:9901001.
  • 40
    Klink R, De Kerkhove d’Exaerde A, Zoli M, Changeux J-P. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 2001;21:14521463.
  • 41
    Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. J Neurobiol 2002;53:606617.
  • 42
    Mansvelder HD, Keath JR, McGehee DS. Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas. Neuron 2002;33:905919.
  • 43
    Klejbor I, Domaradzka-Pytel B, Ludkiewicz B, Wójcik S, Moryś J. The relationships between neurons containing dopamine and nitric oxide synthase in the ventral tegmental area. Folia Histochem Cytobio 2004;42:8387.
  • 44
    Del Bel E, Bermúdez-Echeverry M, Salum C, Raisman-Vozari R. Nitric oxide system and basal ganglia physiopathology. In: Di GiovanniG, editor. The basal ganglia pathophysiology: Recent advances. Kerala : Transworld Research Network, 2007;129158.
  • 45
    Exley R, Cragg SJ. Presynaptic nicotinic receptors: A dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br J Pharmacol 2008;153(Suppl 1):S283S297.
  • 46
    Sammut S, Bray KE, West AR. Dopamine D2 receptor-dependent modulation of striatal NO synthase activity. Psychopharmacology 2007;191:793803.
  • 47
    Sammut S, Dec A, Mitchell D, Linardakis J, Ortiguela M, West AR. Phasic dopaminergic transmission increases NO efflux in the rat dorsal striatum via a neuronal NOS and a dopamine D(1/5) receptor-dependent mechanism. Neuropsychopharmacology 2006;31:493505.
  • 48
    Martin JL, Itzhak Y. 7-Nitroindazole blocks nicotine-induced conditioned place preference but not LiCl-induced conditioned place aversion. Neuroreport 2000;11:947949.
  • 49
    Malin DH, Lake JR, Shenoi M, Upchurch TP, Johnson SC, Schweinle WE, Cadle CD. The nitric oxide synthesis inhibitor nitro-L-arginine (L-NNA) attenuates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 1998;140:371377.
  • 50
    Adams ML, Cicero T. Nitric oxide mediates mecamylamine- and naloxone-precipitated nicotine withdrawal. Eur J Pharmacol 1998;345:R1R2.
  • 51
    Jain R, Mukherjee K, Mohan D. Effects of nitric oxide synthase inhibitors in attenuating nicotine withdrawal in rats. Pharmacol Biochem Behav 2008;88:473480.
  • 52
    Shim I, Kim HT, Kim YH, et al. Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat. Eur J Pharmocol 2002;443:119124.
  • 53
    Ulusu U, Uzbay IT, Kayir H, Alici T, Karakas S. Evidence for the role of nitric oxide in nicotine-induced locomotor sensitization in mice. Psychopharmacology (Berl) 2005;178:500504.
  • 54
    Hong SK, Jung IS, Bang SA, Kim SE. Effect of nitric oxide synthase inhibitor and NMDA receptor antagonist on the development of nicotine sensitization of nucleus accumbens dopamine release: An in vivo microdialysis study. Neurosci Lett 2006;409:220223.
  • 55
    Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis 2008;3:4553.
  • 56
    Dhir A, Kulkarni SK. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007;568:177185.